Lal S, Nair N P
Douglas Hospital Research Centre, Verdun, Québec, Canada.
Acta Psychiatr Scand. 1992 Mar;85(3):243-5. doi: 10.1111/j.1600-0447.1992.tb08603.x.
Levomepromazine (LMP) unexpectedly improved 16 of 23 chronic treatment-resistant schizophrenic patients who were hospitalized in most cases for at least 2 years and who manifested positive symptoms, irritability and, in many cases, restlessness, hostility, uncooperativeness, poor concentration and aggressive behavior. Improvement led to discharge in 7 (6 to a foster home), placement on a waiting list for a foster home in 4 and improved behavior and autonomy in 5 patients. Five subjects developed seizures and 1 agranulocytosis. Whether improvement with LMP is caused by unique antischizophrenic properties or by diminished liability to induce side effects such as akathisia, a formal controlled study of LMP in treatment-resistant schizophrenia is merited.
甲氧异丁嗪（LMP）意外地改善了23例慢性难治性精神分裂症患者中的16例，这些患者大多数住院至少2年，表现出阳性症状、易怒，且在许多情况下有坐立不安、敌意、不合作、注意力不集中和攻击行为。改善后，7例患者出院（6例进入寄养家庭），4例被列入寄养家庭等候名单，5例患者的行为和自主性得到改善。5名受试者出现癫痫发作，1名出现粒细胞缺乏症。LMP的改善是由独特的抗精神分裂症特性引起，还是由诱发静坐不能等副作用的可能性降低所致，值得对LMP在难治性精神分裂症中的应用进行正式对照研究。
